Stuart A Scott

Summary

Affiliation: Mount Sinai School of Medicine
Country: USA

Publications

  1. doi request reprint Antiplatelet drug interactions with proton pump inhibitors
    Stuart A Scott
    Icahn School of Medicine at Mount Sinai, Department of Genetics and Genomic Sciences, One Gustave L Levy Place, Box 1497, New York, NY 10029, USA 1 212 241 3780 1 212 241 0139
    Expert Opin Drug Metab Toxicol 10:175-89. 2014
  2. doi request reprint An allele-specific PCR system for rapid detection and discrimination of the CYP2C19∗4A, ∗4B, and ∗17 alleles: implications for clopidogrel response testing
    Stuart A Scott
    Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York Electronic address
    J Mol Diagn 15:783-9. 2013
  3. pmc Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation
    Naoto Takahashi
    Dept of Hematology Nephrology and Rheumatology, Akita Univ Graduate School of Medicine, Akita, Japan
    J Hematol Oncol 5:23. 2012
  4. pmc Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness
    S A Scott
    Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, NY 10029, USA
    Pharmacogenomics J 12:297-305. 2012
  5. pmc Copy number variation and warfarin dosing: evaluation of CYP2C9, VKORC1, CYP4F2, GGCX and CALU
    Stuart A Scott
    Department of Genetics and Genomic Sciences, Box 1497, Mount Sinai School of Medicine, 1428 Madison Avenue, New York, NY 10029, USA
    Pharmacogenomics 13:297-307. 2012
  6. pmc Personalizing medicine with clinical pharmacogenetics
    Stuart A Scott
    Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, USA
    Genet Med 13:987-95. 2011
  7. pmc CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing
    Stuart A Scott
    Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine of New York University, New York, NY 10029, USA
    Pharmacogenomics 10:1243-55. 2009
  8. pmc Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations
    Stuart A Scott
    Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine of New York University, New York, NY 10029, USA
    Am J Hum Genet 82:495-500. 2008
  9. pmc Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups
    Stuart A Scott
    Department of Genetics and Genomic Sciences, Box 1498, Mount Sinai School of Medicine of New York University, Fifth Avenue at 100th Street, New York, NY 10029, USA
    Pharmacogenomics 11:781-91. 2010
  10. doi request reprint CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population
    Stuart A Scott
    Mount Sinai School of Medicine of New York University, Department of Genetics and Genomic Sciences, Box 1498, Fifth Avenue at 100th Street, New York, NY 10029, USA
    Pharmacogenomics 8:721-30. 2007

Collaborators

Detail Information

Publications17

  1. doi request reprint Antiplatelet drug interactions with proton pump inhibitors
    Stuart A Scott
    Icahn School of Medicine at Mount Sinai, Department of Genetics and Genomic Sciences, One Gustave L Levy Place, Box 1497, New York, NY 10029, USA 1 212 241 3780 1 212 241 0139
    Expert Opin Drug Metab Toxicol 10:175-89. 2014
    ..Importantly, a pharmacological interaction between clopidogrel and some PPIs has been proposed based on mutual CYP450-dependent metabolism, but available evidence is inconsistent...
  2. doi request reprint An allele-specific PCR system for rapid detection and discrimination of the CYP2C19∗4A, ∗4B, and ∗17 alleles: implications for clopidogrel response testing
    Stuart A Scott
    Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York Electronic address
    J Mol Diagn 15:783-9. 2013
    ....
  3. pmc Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation
    Naoto Takahashi
    Dept of Hematology Nephrology and Rheumatology, Akita Univ Graduate School of Medicine, Akita, Japan
    J Hematol Oncol 5:23. 2012
    ..Despite the potent inhibition of BCR-ABL kinase by dasatinib, little is known about the relationship between dasatinib pharmacokinetics and the emergence of kinase domain mutations in vivo...
  4. pmc Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness
    S A Scott
    Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, NY 10029, USA
    Pharmacogenomics J 12:297-305. 2012
    ..Combining CYP2C19 and ABCB1 identified ∼1 in 3 AJ and ∼1 in 2 SJ individuals at increased risk for adverse responses to clopidogrel. These data underscore the importance of including *4B and *17 when clinically genotyping CYP2C19...
  5. pmc Copy number variation and warfarin dosing: evaluation of CYP2C9, VKORC1, CYP4F2, GGCX and CALU
    Stuart A Scott
    Department of Genetics and Genomic Sciences, Box 1497, Mount Sinai School of Medicine, 1428 Madison Avenue, New York, NY 10029, USA
    Pharmacogenomics 13:297-307. 2012
    ....
  6. pmc Personalizing medicine with clinical pharmacogenetics
    Stuart A Scott
    Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, USA
    Genet Med 13:987-95. 2011
    ..This review presents some of the current opportunities and challenges with implementing clinical pharmacogenetic testing...
  7. pmc CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing
    Stuart A Scott
    Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine of New York University, New York, NY 10029, USA
    Pharmacogenomics 10:1243-55. 2009
    ..1173C>T) commonly found among Caucasians. Therefore, this study sought to identify other CYP2C9 and VKORC1 alleles important in warfarin dose variability and to determine their frequencies in different racial and ethnic groups...
  8. pmc Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations
    Stuart A Scott
    Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine of New York University, New York, NY 10029, USA
    Am J Hum Genet 82:495-500. 2008
    ..1639G-->A) or "resistant" (VKORC1 p.D36Y) allele, indicating that each group has different warfarin pharmacogenetics and would benefit from genotype-based dose predictions...
  9. pmc Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups
    Stuart A Scott
    Department of Genetics and Genomic Sciences, Box 1498, Mount Sinai School of Medicine of New York University, Fifth Avenue at 100th Street, New York, NY 10029, USA
    Pharmacogenomics 11:781-91. 2010
    ..Thus, we determined the individual and combined frequencies of important CYP2C9, VKORC1 and CYP4F2 variants in several racial/ethnic groups...
  10. doi request reprint CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population
    Stuart A Scott
    Mount Sinai School of Medicine of New York University, Department of Genetics and Genomic Sciences, Box 1498, Fifth Avenue at 100th Street, New York, NY 10029, USA
    Pharmacogenomics 8:721-30. 2007
    ..To determine and compare the cytochrome P450 (CYP)2C9, CYP2C19 and CYP2D6 allele and genotype frequencies in the Ashkenazi Jewish (AJ) population with other populations...
  11. pmc Frequency of the cholesteryl ester storage disease common LIPA E8SJM mutation (c.894G>A) in various racial and ethnic groups
    Stuart A Scott
    Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
    Hepatology 58:958-65. 2013
    ..Moreover, future studies on CESD prevalence in African and Asian populations may require full-gene LIPA sequencing to determine heterozygote frequencies, since c.894G>A is not common in these racial groups...
  12. doi request reprint An Ashkenazi Jewish SMN1 haplotype specific to duplication alleles improves pan-ethnic carrier screening for spinal muscular atrophy
    Minjie Luo
    Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine of New York University, New York, New York, USA
    Genet Med 16:149-56. 2014
    ..Genet Med 16 2, 149-156. ..
  13. pmc Experience with carrier screening and prenatal diagnosis for 16 Ashkenazi Jewish genetic diseases
    Stuart A Scott
    Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine of New York University, New York, NY 10029, USA
    Hum Mutat 31:1240-50. 2010
    ..Together, these data indicate the general acceptance, carrier frequencies, and prenatal testing results for an expanded panel of 16 diseases in the AJ population...
  14. doi request reprint Warfarin pharmacogenetics: a controlled dose-response study in healthy subjects
    Daniella L Kadian-Dodov
    Vascular Medicine Section, The Zena and Michael A Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
    Vasc Med 18:290-7. 2013
    ..In conclusion, genotype-guided warfarin-dosing algorithms may rely more on genetic variables in healthier individuals than in patients with clinical confounders...
  15. pmc Large inverted repeats within Xp11.2 are present at the breakpoints of isodicentric X chromosomes in Turner syndrome
    Stuart A Scott
    Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine of New York University, New York 10029, USA
    Hum Mol Genet 19:3383-93. 2010
    ..2 that lead to isodicentric chromosome formation and translocations are probably not random and suggest that the complex repetitive architecture of this region predisposes it to rearrangements, some of which are recurrent...
  16. doi request reprint Combined and independent impact of diabetes mellitus and chronic kidney disease on residual platelet reactivity
    Usman Baber
    Cardiac Catheterization Laboratory, Mount Sinai Medical Center, One Gustave L Levy Place, New York, NY 10029, USA
    Thromb Haemost 110:118-23. 2013
    ..Whether more potent platelet inhibitors may improve outcomes among patients with both abnormalities warrants investigation. ..
  17. doi request reprint Detection of low-level mosaicism and placental mosaicism by oligonucleotide array comparative genomic hybridization
    Stuart A Scott
    Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine of New York University, New York City, New York 10029, USA
    Genet Med 12:85-92. 2010
    ..To determine the sensitivity of whole-genome oligonucleotide array comparative genomic hybridization for the detection of mosaic cytogenetic abnormalities...